Shenzhen Noposion Crop Science Co., Ltd. (SHE:002215)
11.23
+0.13 (1.17%)
Feb 6, 2026, 3:04 PM CST
SHE:002215 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,456 | 5,265 | 4,103 | 4,250 | 4,477 | 4,113 |
Other Revenue | 23.51 | 23.51 | 16.45 | 15.08 | 23.87 | 17.95 |
| 5,480 | 5,288 | 4,120 | 4,265 | 4,501 | 4,131 | |
Revenue Growth (YoY) | 10.60% | 28.37% | -3.41% | -5.23% | 8.94% | 1.80% |
Cost of Revenue | 3,383 | 3,327 | 2,916 | 3,121 | 3,297 | 3,092 |
Gross Profit | 2,097 | 1,961 | 1,203 | 1,144 | 1,203 | 1,039 |
Selling, General & Admin | 968.26 | 976.4 | 684.85 | 643.71 | 703.1 | 658.72 |
Research & Development | 130.92 | 142.95 | 118.9 | 125.62 | 107.38 | 99.03 |
Other Operating Expenses | 44.07 | 7.79 | -2.88 | 16 | 12.89 | 10.84 |
Operating Expenses | 1,220 | 1,233 | 890.63 | 835.49 | 861.85 | 824.61 |
Operating Income | 876.23 | 728.1 | 312.61 | 308.7 | 341.63 | 214.44 |
Interest Expense | -91.07 | -103.08 | -97.56 | -96.85 | -68.06 | -66.68 |
Interest & Investment Income | 45.16 | 69.63 | 51.05 | 81.57 | 47.04 | 31.5 |
Currency Exchange Gain (Loss) | 2.48 | 2.48 | 1.12 | 0.01 | -1.09 | -2.74 |
Other Non Operating Income (Expenses) | -36.25 | -39.14 | -3.05 | -11.37 | -10.02 | -2.59 |
EBT Excluding Unusual Items | 796.55 | 657.99 | 264.17 | 282.06 | 309.5 | 173.93 |
Impairment of Goodwill | -8.1 | -8.1 | -9.21 | -14.48 | -10.41 | -5.48 |
Gain (Loss) on Sale of Investments | -65.5 | -65.5 | -13.4 | - | -7.11 | -11.46 |
Gain (Loss) on Sale of Assets | -3.73 | -16.73 | -0.46 | 28.81 | 8.18 | -0.53 |
Asset Writedown | -25.2 | -29.3 | -22.57 | -9.21 | -12.03 | -1.29 |
Other Unusual Items | -8.91 | 31.93 | -1.53 | 57.48 | 54.87 | 38.86 |
Pretax Income | 685.11 | 570.3 | 217 | 344.66 | 343.01 | 194.03 |
Income Tax Expense | 23.82 | 9.2 | 12.43 | 17.48 | 45.74 | 19.35 |
Earnings From Continuing Operations | 661.3 | 561.1 | 204.57 | 327.18 | 297.26 | 174.68 |
Minority Interest in Earnings | 11.21 | 23.49 | 31.06 | 1.26 | 8.07 | -7.77 |
Net Income | 672.51 | 584.59 | 235.63 | 328.44 | 305.33 | 166.91 |
Net Income to Common | 672.51 | 584.59 | 235.63 | 328.44 | 305.33 | 166.91 |
Net Income Growth | 51.77% | 148.10% | -28.26% | 7.57% | 82.93% | -29.28% |
Shares Outstanding (Basic) | 986 | 996 | 978 | 977 | 903 | 899 |
Shares Outstanding (Diluted) | 1,013 | 1,020 | 1,003 | 996 | 919 | 911 |
Shares Change (YoY) | -0.51% | 1.75% | 0.62% | 8.38% | 0.91% | 0.76% |
EPS (Basic) | 0.68 | 0.59 | 0.24 | 0.34 | 0.34 | 0.19 |
EPS (Diluted) | 0.66 | 0.57 | 0.23 | 0.33 | 0.33 | 0.18 |
EPS Growth | 52.54% | 143.83% | -28.70% | -0.75% | 81.28% | -29.81% |
Free Cash Flow | -98.34 | 118.08 | -344.92 | -730.27 | -84.68 | 286.1 |
Free Cash Flow Per Share | -0.10 | 0.12 | -0.34 | -0.73 | -0.09 | 0.31 |
Dividend Per Share | 0.350 | 0.350 | 0.150 | 0.150 | 0.200 | 0.100 |
Dividend Growth | 133.33% | 133.33% | - | -25.00% | 100.00% | -33.33% |
Gross Margin | 38.26% | 37.08% | 29.21% | 26.83% | 26.74% | 25.15% |
Operating Margin | 15.99% | 13.77% | 7.59% | 7.24% | 7.59% | 5.19% |
Profit Margin | 12.27% | 11.05% | 5.72% | 7.70% | 6.78% | 4.04% |
Free Cash Flow Margin | -1.80% | 2.23% | -8.37% | -17.12% | -1.88% | 6.93% |
EBITDA | 1,362 | 1,100 | 532.93 | 439.55 | 458.02 | 314.96 |
EBITDA Margin | 24.85% | 20.80% | 12.94% | 10.31% | 10.18% | 7.62% |
D&A For EBITDA | 485.49 | 371.84 | 220.32 | 130.85 | 116.4 | 100.52 |
EBIT | 876.23 | 728.1 | 312.61 | 308.7 | 341.63 | 214.44 |
EBIT Margin | 15.99% | 13.77% | 7.59% | 7.24% | 7.59% | 5.19% |
Effective Tax Rate | 3.48% | 1.61% | 5.73% | 5.07% | 13.34% | 9.97% |
Revenue as Reported | 191.69 | - | - | 4,265 | 4,501 | 4,131 |
Advertising Expenses | - | 65.04 | 65.56 | - | - | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.